Research & Innovation

Gastric / Esophageal Clinical Trials

Clinical Trials

Merck MK7902-014

Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy Compared with Standard of Care as First-line Intervention in Participants with Metastatic Esophageal Carcinoma (NCT04949256).

Physician & Study Coordinator

Study Coordinator

Vivian Colon
phone: 484-658-1793




The purpose of this study is to compare two treatment regimens in people with advanced esophageal cancer. Treatment is randomly assigned to pembrolizumab and chemotherapy with or without the addition of Lenvatinib. The study will evaluate the safety and tolerability of these treatments as well as the effectiveness of Lenvatinib and pembrolizumab combined with chemotherapy to stop the cancer from spreading.


Eligibility Criteria

Your doctor will determine whether this clinical trial is an appropriate option for you. Some key eligibility criteria are as follows:

  • Patients must have a confirmed diagnosis of metastatic squamous cell carcinoma of the esophagus
  • Patients must not have received prior therapy for metastatic esophageal cancer
  • Patients must have measurable disease that can be followed for disease response while on study
  • Patients must have adequately controlled blood pressure with or without antihypertensive medications
  • Tissue from prior biopsy/surgery will be sent for PD-L1 composite score and must be completed prior to study enrollment
  • No major surgery within 3 weeks of study intervention
  • No radiation therapy within 2 weeks of study intervention
  • Patients must have an ECOG performance status of 0-1